These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15288287)

  • 61. Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.
    Dowsett M; Lønning PE; Davidson NE
    J Clin Oncol; 2016 May; 34(14):1580-3. PubMed ID: 26729430
    [No Abstract]   [Full Text] [Related]  

  • 62. Gynaecological effects of tamoxifen.
    Ismail SM
    J Clin Pathol; 1999 Feb; 52(2):83-8. PubMed ID: 10396232
    [No Abstract]   [Full Text] [Related]  

  • 63. Aromatase inhibitors might be more effective when they are given 2-3 months later after the administration of luteinizing hormone-releasing hormone agonists in younger premenopausal breast cancer patients.
    Altundag K
    J BUON; 2018; 23(6):1928. PubMed ID: 30610824
    [No Abstract]   [Full Text] [Related]  

  • 64. [Does tamoxifen have a negative effect on survival chances of premenopausal women with locoregional recurrence of breast carcinoma?].
    Sauer H
    Strahlenther Onkol; 1997 Jul; 173(7):390. PubMed ID: 9265263
    [No Abstract]   [Full Text] [Related]  

  • 65. Side effects of therapy: case 2. Tamoxifen and uterine abnormalities.
    Buijs C; Willemse PH; Tinga DJ; Hollema H; de Vries EG; Mourits MJ
    J Clin Oncol; 2004 Jun; 22(12):2505-7. PubMed ID: 15197214
    [No Abstract]   [Full Text] [Related]  

  • 66. Challenges in the gynecologic care of premenopausal women with breast cancer.
    Bakkum-Gamez JN; Laughlin SK; Jensen JR; Akogyeram CO; Pruthi S
    Mayo Clin Proc; 2011 Mar; 86(3):229-40. PubMed ID: 21307388
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Patient and provider factors associated with the noninitiation of tamoxifen for young women at high-risk for the development of breast cancer.
    Kandagatla P; Rizk NN; Dokic D; Kochkodan J; Estevez S; Yanik M; Goranta S; Huber-Keener K; Jeruss JS
    Breast J; 2020 Mar; 26(3):464-468. PubMed ID: 31538708
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [LH-RH analogues in metastatic breast cancer: first results].
    Terzoli E; Izzo F; Nisticò C; Lucatelli S; Ranuzzi M
    G Ital Oncol; 1988; 8(2):59-63. PubMed ID: 3065224
    [No Abstract]   [Full Text] [Related]  

  • 69. Breast cancer: effect of tamoxifen on the mineral density of bone.
    Zylberberg B; Dormont D; Perrot N; Uzan S
    Eur J Obstet Gynecol Reprod Biol; 1993 Dec; 52(2):147-8. PubMed ID: 8157145
    [No Abstract]   [Full Text] [Related]  

  • 70. Tamoxifen Decreases Mortality, but How?
    Bhattacharya P; Abderrahman B; Jordan VC
    J Clin Oncol; 2017 Jan; 35(3):379. PubMed ID: 28095275
    [No Abstract]   [Full Text] [Related]  

  • 71. LH-RH agonists in the treatment of premenopausal patients with advanced breast cancer.
    Höffken K
    Recent Results Cancer Res; 1992; 124():91-104. PubMed ID: 1615223
    [No Abstract]   [Full Text] [Related]  

  • 72. Re: Meta-analysis and economic evaluation of LH-RH agonists' depot formulations in advanced prostatic carcinoma.
    Oh PI; Manzi P; Parison D
    Can J Urol; 1998 Dec; 5(5):664. PubMed ID: 11319044
    [No Abstract]   [Full Text] [Related]  

  • 73. Re: Meta-analysis and economic evaluation of LH-RH agonists' depot formulations in advanced prostatic carcinoma.
    Einarson TR; Yannicelli D
    Can J Urol; 1998 Dec; 5(5):666. PubMed ID: 11319045
    [No Abstract]   [Full Text] [Related]  

  • 74. Reply by author, Re: Meta-analysis and economic evaluation of LH-RH agonists' depot formulations in advanced prostatic carcinoma.
    Alloul K
    Can J Urol; 1998 Dec; 5(5):668. PubMed ID: 11319046
    [No Abstract]   [Full Text] [Related]  

  • 75. Reply by editor, Re: Meta-analysis and economic evaluation of LH-RH agonists' depot formulations in advanced prostatic carcinoma.
    Goel V
    Can J Urol; 1998 Dec; 5(5):671. PubMed ID: 11319047
    [No Abstract]   [Full Text] [Related]  

  • 76. [Detection of female cancer in Gottwaldov Region].
    KRAL V
    Cesk Gynekol; 1957 Feb; 22(1-2):116-9. PubMed ID: 13413975
    [No Abstract]   [Full Text] [Related]  

  • 77. Gynaecological problems of adolescence.
    BARNES J
    Practitioner; 1957 Mar; 178(1065):316-22. PubMed ID: 13408185
    [No Abstract]   [Full Text] [Related]  

  • 78. Some interesting gynaecological cases.
    PRESTON PG
    East Afr Med J; 1953 Nov; 30(11):447-58. PubMed ID: 13127815
    [No Abstract]   [Full Text] [Related]  

  • 79. LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen.
    Berlière M; Galant C; Marques G; Piette P; Duck L; Fellah L; Donnez J; Machiels JP
    Eur J Cancer; 2004 Aug; 40(12):1855-61. PubMed ID: 15288287
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
    J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.